California's stem cell research institute has received little attention of late, and agency officials probably prefer it that way. But while the media have been off covering sex scandals involving mayors and astronauts, the Institute for Regenerative Medicine has been quietly preparing, for the first time in its two-year history, to dispense millions of public dollars for embryonic stem cell research.
The institute's oversight committee will meet in San Francisco this week to decide on roughly $24 million in grants for new stem cell researchers. While that may be pocket change compared with the $3 billion that voters authorized when they endorsed Proposition 71 in 2004, this initial research funding is historic, and other grants totaling about $100 million will soon follow this year.
Taxpayers curious about how their money will be spent can go to the institute's Web site -- www.cirm.ca.gov/publicsummaries/PublicList.html -- to see the 30 scientific proposals recommended for funding. The site also includes 200 other projects that didn't make the cut, with summaries and scientific assessments -- some of them surprisingly blunt -- about each proposal.
Once the institute's oversight board makes its final decision, it will identify the names and affiliations of scientists receiving grants.
Digital Access for only $0.99
For the most comprehensive local coverage, subscribe today.
We have some questions about the stem cell institute's procedures for reviewing proposals and selecting projects to fund.
Scientists from outside states do much of the review work, and are not required to publicly disclose their potential conflicts of interest. Undoubtedly, some of those scientists have outside consulting work, or personal relationships with researchers seeking funding, that could affect grant decisions.
Yet under the institute's shrouded procedures, it is impossible for anyone to be assured that grant reviewers are recusing themselves at the proper times.
This lack of public disclosure is the single most glaring problem with the institute. While it is momentous that California is now on the leading edge of financing embryonic stem cell research, the institute still hasn't adopted a transparent procedure for policing potential conflicts. The Legislature needs to correct that.